# Redmile Group

> Redmile Group is a VC fund backing Biotechnology and Health Care. See 177 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 177
- Last investment: Aug 2026
- Lead investor: 27%
- Fund size: $675M
- Last fund: Mar 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/redmile-group/about/
- Website: http://redmilegroup.com

Redmile Group is a healthcare investment organization that makes venture, growth, and crossover investing across healthcare.

## Contacts

5 contacts available for Redmile Group. Shizune tracks 4 team members at Redmile Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/redmile-group?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $46M–$170M |
| Series C | $40M–$200M |
| Post-IPO Equity | $25M–$275M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 88 | 50% |
| Health Care | 61 | 34% |
| Therapeutics | 41 | 23% |
| Medical | 38 | 21% |
| Pharmaceutical | 28 | 16% |

34 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 32 | 18% |
| Series B | 30 | 17% |
| Post-IPO Equity | 24 | 14% |
| Series A | 13 | 7% |
| Series D | 10 | 6% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 77 | 44% |
| United Kingdom | 6 | 3% |
| France | 5 | 3% |
| Germany | 3 | 2% |
| Canada | 2 | 1% |

12 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Robert Faulkner | Managing Director | 1 | https://shizune.co/investors/profile/rob-faulkner |
| Gerard van Hamel Platerink | Managing Director | 2 | https://shizune.co/investors/profile/gerard-van-hamel-platerink |
| Mike Lee | Managing Director/Co-Founder | 0 | https://shizune.co/investors/profile/mike-lee-4280 |
| Ming Fang | Managing Director | 1 | https://shizune.co/investors/profile/ming-fang |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bios Life | Bios Life is a technology-enabled healthcare company built to empower individuals to proactively manage their cancer risk, redefining personalized cancer screening and survivorship. | $25M | Seed | Aug 10, 2026 |  |
| Obsidian Therapeutics | Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with newfunctions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies. | $350M | Post-IPO Equity | Aug 04, 2026 |  |
| Absci | Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $100M | Post-IPO Equity | Jun 24, 2026 |  |
| Climb Bio | Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $110M | Post-IPO Equity | Apr 28, 2026 |  |
| Ambrosia Biosciences | Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders. | $100M | Series B | Mar 31, 2026 |  |
| ALX Oncology | ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company.The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University.This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1. | $150M | Post-IPO Equity | Jan 30, 2026 |  |
| Sensorion | Sensorion, a Clapiers, France-based biopharmaceutical company specifically dedicated to the development of innovative and targeted therapeutic solutions to treat vestibular deficits. | $71.5M | Post-IPO Equity | Jan 28, 2026 |  |
| Impulse Dynamics | Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF). The Company’s developments are based on its proprietary technology for administering Cardiac Contractility Modulation therapy. This form of treatment has been shown in European clinical trials to produce an immediateand powerful modulating effect on cardiac cells, resulting in clinically meaningful increases incardiac performance.Impulse Dynamics is spearheaded by a team of professionals including, scientists, physicians, and engineers. The Company carries out research programs in major universities and hospitals throughout the world, and is currently engaged in clinical trials in Europe and in the United States. The Optimizer with Cardiac Contractility Modulation therapy, is CE marked. See Clinical Data for more information. | $158M |  | Dec 10, 2025 |  |
| Bambusa Therapeutics | Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies. |  | Series A | Nov 17, 2025 |  |
| Electra Therapeutics | Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. | $183M | Series C | Oct 22, 2025 |  |

10 of 177 investments shown.

## Co-investors
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 29 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 26 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 23 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 21 deals together
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 21 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 20 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Redmile Group invest in?

Redmile Group invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series C and Series B stage. Most of the 177 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Redmile Group's check size?

Redmile Group typically joins rounds of $46M–$170M at Series B, $40M–$200M at Series C and $25M–$275M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Redmile Group participates in.

### How do I contact Redmile Group?

Public channels for Redmile Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Redmile Group?

The team at Redmile Group includes Robert Faulkner (Managing Director), Gerard van Hamel Platerink (Managing Director) and Mike Lee (Managing Director/Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co